Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex.
1. The present study investigated the binding characteristics of various ligands to cannabinoid CB(1) receptors in human neocortex and amygdala. In addition, the functionality of CB(1) receptors in the human neocortex was assessed by examining the effects of CB(1) receptor ligands on evoked [(3)H]-dopamine (DA) release in superfused brain slices and on synaptosomal cAMP accumulation. 2. Saturation-binding assays in human neocortical and amygdala synaptosomes using a radiolabelled cannabinoid receptor agonist ([(3)H]-CP55.940) revealed pK(d) values of 8.96 and 8.63, respectively. The numbers of binding sites (B(max)) were 3.99 and 2.67 pmol (mg protein)(-1), respectively. 3. Various cannabinoid receptor ligands inhibited [(3)H]-CP55.940 binding with rank order potencies corresponding to those of previous studies in animal tissues. 4. Electrically evoked [(3)H]-DA release from human neocortical slices was inhibited by CP55.940 (IC(50) 6.76 nm, I(max) 65%) and strongly enhanced by the cannabinoid receptor antagonist AM251. However, [(3)H]-DA release was not influenced in rat neocortex. In human tissue, the estimated endocannabinoid concentration in the biophase of the release-modulating CB(1) receptors was 1.07 nm, expressed in CP55.940 units. 5. K(+)-evoked [(3)H]-DA release in the presence of tetrodotoxin (TTX) was strongly inhibited by CP55.940 in humans, but not in rats. 6. In human tissue, CP55.940 inhibited forskolin-stimulated cAMP accumulation (IC(50) 20.89 nm, I(max) 35%). AM251 blocked this effect and per se increased forskolin-stimulated cAMP accumulation by approximately 20%. 7. In conclusion, cannabinoids modulate [(3)H]-DA release and adenylyl cyclase activity in the human neocortex. CB(1) receptors are located on dopaminergic nerve terminals and seem to be tonically activated by endocannabinoids.
Sektion Klinische Neuropharmakologie der Neurologischen Universitätsklinik, Neurozentrum, Breisacherstrasse 64, D-79106 Freiburg, Germany.
M
M
Steffens
C
C
Engler
J
J
Zentner
T J
TJ
Feuerstein
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000679:Amygdala / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001095:Arachidonic Acids / Q000493:pharmacokinetics; D048588:Benzoxazines; D001665:Binding Sites / Q000187:drug effects; D005576:Colforsin / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D000242:Cyclic AMP / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D003511:Cyclohexanols / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D004298:Dopamine / Q000378:metabolism* / Q000493:pharmacokinetics; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004558:Electric Stimulation; D063388:Endocannabinoids; D005260:Female; D006801:Humans; D008024:Ligands; D008297:Male; D009025:Morpholines / Q000493:pharmacokinetics; D009281:Naphthalenes / Q000493:pharmacokinetics; D019579:Neocortex / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D010880:Piperidines / Q000493:pharmacokinetics; D053284:Polyunsaturated Alkamides; D011188:Potassium / Q000378:metabolism; D011720:Pyrazoles / Q000493:pharmacokinetics; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects / Q000502:physiology*; D013574:Synaptosomes / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D013779:Tetrodotoxin / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D014316:Tritium
D001095:Arachidonic Acids; D048588:Benzoxazines; D003511:Cyclohexanols; D063388:Endocannabinoids; D008024:Ligands; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D014316:Tritium; C052413:delta(9-11)-tetrahydrocannabinol; D005576:Colforsin; C103505:AM 251; D013779:Tetrodotoxin; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D013759:Dronabinol; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D011188:Potassium; C078814:anandamide; D004298:Dopamine